Navigation Links
Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
Date:5/20/2008

Data Presented at the 2008 International Conference of the American

Thoracic Society

TORONTO, May 20 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and Laboratorios Almirall, S.A. today presented results from four clinical trials assessing the efficacy and safety of aclidinium bromide, an investigational treatment for chronic obstructive pulmonary disease (COPD). Data from four preclinical studies further describing the properties of aclidinium were also presented at the meeting.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Presentations included data from a 464-patient randomized, double-blind, four-week, Phase IIb study that evaluated both the efficacy and tolerability of once-daily aclidinium (25 mcg, 50 mcg, 100 mcg, 200 mcg or 400 mcg) or placebo in patients with moderate to severe COPD. An open-label tiotropium (18 mcg) arm was included as an active control. The study demonstrated aclidinium (200 mcg and 400 mcg), administered via a multi-dose dry powder inhaler, significantly increased trough (24-hour) forced expiratory volume in one second (FEV1) -- an important measure of lung function -- on Day 29 compared with placebo (p<0.05 vs placebo). There was a dose response observed for lung function improvement with once-daily aclidinium. Aclidinium was well tolerated, with no dose-dependent effect on ECG, laboratory parameters, or adverse events. Overall, the most frequently reported adverse events were headache (4.1% of patients), dry mouth (2.8% of patients), exacerbation of chronic obstructive airways disease (1.7% of patients) and cough (1.7% of patients). Based on these results, aclidinium 200 mcg administered once every 24 hours was selected as the dose for investigation in the two ongoing Phase III clinical trials, ACCLAIM COPD I and II, which are expected to report out during the second ha
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
2. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
3. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
4. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
5. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
8. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
9. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
10. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
11. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- The Board of Directors of VirtualScopics, Inc. (NASDAQ: ... trial imaging solutions, announced today that Eric T. ... executive officer, effective immediately.  Mr. Converse joined the company,s ... the positions of interim president and chief executive officer ... E. Phelps , Ph.D., chairman of the company,s Board ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... in Consumer Healthcare by Application, Sensor Type & by ... 2020" report to their offering. ... an increasing momentum for consumer healthcare monitoring and sensing ... consumer healthcare will lessen the healthcare cost of the ...
(Date:7/23/2014)... OSCEOLA, Wis. and MOUNTAIN VIEW, ... Inc. ("Surpass"), a recognized leader in translational preclinical research, ... at www.surpassinc.com ), signaling the transformation of Surpass, ... integrated innovation partner for our customers. This press release ... that two integral hires were added to the Silicon ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Sept. 30, 2011 Haemonetics Corporation (NYSE: ... quarter of its 2012 fiscal year on October 31, ... hold a webcast to discuss and answer questions about ... 31, 2011. Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4204617 ...
... Sept. 29, 2011 Boston Scientific Corporation (NYSE: ... ( NE ural C ardiac T her A ... a prospective, randomized, international clinical feasibility study designed to assess ... heart failure patients.  The study will evaluate 96 patients with ...
Cached Medicine Technology:Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 2Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 3Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 4
(Date:7/23/2014)... 2014 Thousands of DePuy Pinnacle hip ... a federal multidistrict litigation underway in U.S. District Court, ... to an Order dated July 18th, U.S. District Judge ... of a $1,000 fee for the preservation and return ... other things, the Order noted that there is no ...
(Date:7/23/2014)... 2014 Bodybuilding.com, the Internet’s most-visited bodybuilding ... nutritional supplements, has officially opened the polls for their ... the fastest growing sports nutrition company, is up for ... the Year, Best Tasting Protein of the Year- Whey-HD™, ... the year - Whey-HD™, Pre-workout Supplement of the Year ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a ... other behaviors on the autistic spectrum, as well as ... of mental impairment and the most common cause of ... California, Riverside have published a study that ... FXS. Appearing online today (July 23) in the ...
(Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
(Date:7/23/2014)... The voice on the recording was low and calm ... he was infected with the human immunodeficiency virus (HIV) that causes ... thing you know I was on the floor flat on my ... hopeful when the recording ended less than 10 minutes later. “Don’t ... because it is just God setting you up for something ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3
... has developed new guidelines for starting and monitoring treatments ... first JIA guidelines endorsed by the ACR, with the ... Created as a guide for health care providers, ... of multiple medications used in the treatment of JIA, ...
... venues and a lack of motivation even if those ... for adolescent boys, according to recently published research from a ... boys, attitudes led by Lorraine Robbins from MSU,s College of ... the decrease in exercise typically seen in this age group. ...
... , WEDNESDAY, March 30 (HealthDay News) -- Longer periods ... larger brain growth in offspring, which explains why human ... say researchers. They also said the findings from ... offer further proof that breast-feeding is good for brain ...
... at diagnosis for chronic myeloid leukemia (CML) is over 60 ... data are available about the long-term outcome for older patients ... CML. Results from a study published today in ... of Hematology , reveal that age does not affect response ...
... reduced the blood pressure of a 76-year-old woman ... total knee replacement surgery for osteoarthritis (OA). While ... the woman,s blood pressure dropped dramatically when she ... the April issue of Arthritis Care & ...
... HealthDay Reporter , TUESDAY, March 29 (HealthDay News) -- While ... New research suggests that some people with the disease apparently ... kidney and heart disease. In a group of ... years, nearly 43 percent remained free of serious eye disease, ...
Cached Medicine News:Health News:New clinical practice guidelines developed for juvenile idiopathic arthritis 2Health News:New clinical practice guidelines developed for juvenile idiopathic arthritis 3Health News:Lack of motivation, equipment main barriers for exercise for boys 2Health News:Longer Breast-Feeding May Be Key to Bigger Brains 2Health News:Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib 2Health News:Case study reports singing lowers patient's blood pressure prior to surgery 2Health News: Some Type 1 Diabetics Seem Shielded Against Complications 2Health News: Some Type 1 Diabetics Seem Shielded Against Complications 3Health News: Some Type 1 Diabetics Seem Shielded Against Complications 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: